Information was received from a healthcare provider regarding a patient who was implanted with an implantable neurostimulator (ins) for fecal incontinence.Their trial start date was (b)(6) 2023.It was reported that they had a post-pne pelvic hematoma, pain, and bleeding/hemorrhage.Patient (pt) presented to the emergency room (er) the evening of (b)(6) 2023 approximately 4 hours after pne with low back, tailbone and abdominal pain.Ct scan demonstrated pelvic hematoma with active bleeding.Pt was treated by interventional radiology and bleeding was stopped.The bleeding stopped and the patient was still in the er under observation and for pain management.The issue was resolved.Additional information was received from a healthcare professional (hcp) on 2023-10-20.The hcp reported that the patient was admitted to the hospital due the device.The lead placement caused a pelvic hematoma on (b)(6) 2023.They resolved the issue by the embolization of the hematoma.Patient improved inpatient and hematoma decreased and patient had been discharged.
|
Continuation of d10: product id: 309201, lot# unknown, implanted: (b)(6) 2023, product type: screening device.Section d information references the main component of the system.Other relevant device(s) are: product id: 309201, serial/lot #: unknown.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|